筛选条件 共查询到16条结果
排序方式
Reduced emergency room visits and improved medication adherence of an integrated oncology pharmaceutical care practice in China

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021; 27 (6)

Objective We described our initial experience of a new integrated oncology phamaceutical care practice to enhance the quality of pharmacy service and ......

How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021; 27 (4)

Objective The objective of this article was to offer practical operational process for pharmacists to successfully conduct integrated pharmaceutical c......

Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, ; ()

Introduction Nivolumab, a programmed death-1(PD-1) inhibitor antibody, have demonstrated anti-tumor activity for multiple malignancies. Such immune ch......

Apatinib-induced hyperammonemic encephalopathy

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020; 26 (2)

Apatinib is an orally administered small-molecule vascular endothelial growth factor receptor-2 inhibitor that has demonstrated encouraging anticancer......

Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020; 26 (8)

Introduction Acute promyelocytic leukemia is an oncologic emergency. The limited cases reported in the literature have led to poor understanding of th......

A simple method to identify undiagnosed drug-induced liver injury (DILI) and its application in oncology pharmacy practice

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 0; ()

Aims To establish a simple method to identify chemotherapy-induced liver injury among oncological patients. To evaluate current clinical approach to e......

Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019; 25 (6)

When encountering a hypersensitivity reaction to chemotherapy, a dilemma arises whether to continue the current regimen. In our institution, a standar......

JIF:1.83

Translation and validation of the Chinese version of the Cancer Stigma Scale

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019; 25 (7)

Purpose To test the reliability and validity of the Chinese version of the Cancer Stigma Scale (CASS). Methods After translation, back-translation and......

JIF:1.83

Evaluating the adverse effects of melphalan formulations

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019; 25 (7)

Introduction For multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard......

JIF:1.83

Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019; 25 (2)

Many oral anticancer agents are recommended to be given either at least 1 h before or 2 h after a meal, according to the prescribing information. Howe......

JIF:1.83

RETRACTION: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018; 24 (6)

Objectives: To model the cost-utility of trastuzumab combined with docetaxel for patients with HER-2 positive metastatic breast cancer (mBC) without p......

JIF:1.83

Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022; 28 (1)

Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by excessive production of inflammatory cytokines a......

JIF:1.519

Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022; 28 (6)

Introduction Camrelizumab is an antibody against programmed death protein 1 (PD-1) and is one of immune checkpoint inhibitors (ICI). ICI may lead to a......

JIF:1.519

The drugs screened by OncoVee(TM)-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer

期刊: JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022; 28 (6)

Introduction At present, the prognosis of HER2-positive advanced gastric cancer is extremely poor, and some patients fail to benefit from first-line H......

JIF:1.519

共16条页码: 1/2页15条/页